The cost burden of Crohn's disease and ulcerative colitis depending on biologic treatment status - a Danish register-based study.

CD and UC patients receiving biologic treatment had higher average annual healthcare costs and lower average annual production values, compared to patients not receiving biologic treatment. The main healthcare costs drivers were outpatient visit costs and admission costs.